Cohesin haploinsufficiency and inv(16) cooperate to reinforce Fli1 gene transcriptional programs during acute myeloid leukemia initiation and maintenance.
A genetic mutation combination previously thought to slow cancer growth actually accelerates leukemia, but this discovery pinpoints a new therapeutic vulnerability to exploit.
Using an inv(16);Smc3-haploinsufficient mouse model, the authors paradoxically found that cohesin loss accelerates rather than antagonizes inv(16)-driven AML development. Single-cell RNA sequencing of pre-leukemic HSPCs revealed increased chromatin accessibility at Fli1 motifs and elevated Fli1 target gene programs in the haploinsufficient context, and Fli1 knockdown impaired AML maintenance—establishing Fli1 as a previously unrecognized therapeutic vulnerability in cohesin-mutated CBF-AML.
What the study was
- Study design
- mechanistic_in_vivo_mouse_model
- Population
- Inv(16);Smc3-haploinsufficient mouse model plus human CBF-AML patient expression data
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Leukemia
Why it surfaced
Leukemia paper resolving a paradoxical cooperativity between cohesin haploinsufficiency and inv(16) in AML through mechanistically rigorous mouse model + scRNA-seq, and identifying Fli1 as a druggable target in cohesin-mutated AML—directly translatable to a molecularly defined subset of AML.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.